In the course of reinventing, refocusing, and reinvigorating the company, Strongbridge Biopharma has reached a series of pivotal business and clinical milestones.
In December 2016, Strongbridge Biopharma acquired the US rights to KEVEYIS® (dichlorphenamide). This acquisition is part of our commitment to expand our portfolio and help meet the needs of patients with rare and orphan diseases that are underdiagnosed and undertreated.
Recent clinical milestones reflect our focus on rare diseases and our organizational agility in meeting the challenges of drug development.
Last patient enrolled (LPI) in phase 3 SONICS trial of RECORLEV (levoketoconazole) for endogenous Cushing's syndrome
Acquired KEVEYIS (dichlorphenamide) from Taro Pharmaceutical Industries for Primary Periodic Paralysis
Acquired veldoreotide, being studied for acromegaly, from Aspireo Pharmaceuticals
First patient enrolled in phase 3 SONICS trial of RECORLEV in endogenous Cushing's syndrome
RECORLEV received EU orphan drug designation
RECORLEV received US orphan drug designation
Pivoted RECORLEV focus from diabetes to Cushing's syndrome
© 2017 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA™ is a trademark of Strongbridge Biopharma plc.
KEVEYIS® is a registered trademark licensed exclusively in the US to Strongbridge Biopharma plc.
MLR010 V11 10/2017